Growth Metrics

Eli Lilly (LLY) FCF Payout Ratio (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -74.06%
Dec 31, 2025 895.68%
Sep 30, 2025 -79.44%
Jun 30, 2025 -88.77%
Mar 31, 2025 622.30%
Dec 31, 2024 140.97%
Sep 30, 2024 -89.79%
Jun 30, 2024 -25.36%
Mar 31, 2024 984.10%
Dec 31, 2023 -188.29%
Sep 30, 2023 104.36%
Jun 30, 2023 -2,097.91%
Mar 31, 2023 25.83%
Dec 31, 2022 37.99%
Sep 30, 2022 -74.63%
Jun 30, 2022 429.70%
Mar 31, 2022 4.57%
Dec 31, 2021 -34.05%
Sep 30, 2021 -46.22%
Jun 30, 2021 99.55%
Mar 31, 2021 12.61%
Dec 31, 2020 3.65%
Sep 30, 2020 56.05%
Jun 30, 2020 -94.37%
Mar 31, 2020 1,408.21%
Dec 31, 2019 -23.88%
Sep 30, 2019 -67.56%
Jun 30, 2019 -75.48%
Mar 31, 2019 990.48%
Dec 31, 2018 75.64%
Sep 30, 2018 -35.55%
Jun 30, 2018 -83.66%
Mar 31, 2018 596.23%
Dec 31, 2017 26.17%
Sep 30, 2017 -12.91%
Jun 30, 2017 -88.02%
Mar 31, 2017 845.17%
Dec 31, 2016 -9.64%
Sep 30, 2016 -19.85%
Jun 30, 2016 132.46%
Mar 31, 2016 -263.82%
Dec 31, 2015 38.98%
Sep 30, 2015 -14.99%
Jun 30, 2015 138.58%
Mar 31, 2015 -479.45%
Dec 31, 2014 35.15%
Sep 30, 2014 -42.91%
Jun 30, 2014 -91.15%
Mar 31, 2014 1,742.35%
Dec 31, 2013 33.26%
Sep 30, 2013 -14.50%
Jun 30, 2013 -85.19%
Mar 31, 2013 420.82%
Dec 31, 2012 15.25%
Sep 30, 2012 -18.24%
Jun 30, 2012 -35.24%
Mar 31, 2012 134.27%
Dec 31, 2011 12.99%
Sep 30, 2011 -1.84%
Jun 30, 2011 -42.55%
Mar 31, 2011 83.67%
Dec 31, 2010 -19.51%
Sep 30, 2010 11.95%
Jun 30, 2010 -52.83%
Mar 31, 2010 111.33%
Dec 31, 2009 -35.41%
Sep 30, 2009 -34.32%
Jun 30, 2009 109.30%